Cubicin®/Cubicin® RF (daptomycin) – Expanded indication
March 29, 2017 – The FDA approved Merck’s Cubicin/Cubicin RF (daptomycin) for complicated skin and skin structure infections (cSSSI) in pediatric patients (1 to 17 years of age) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).
Top